Islet Cell Autoantibodies in Hepatitis C Treatment
Author Information
Author(s): GAMAL BADRA, IMAM WAKED, CARLO SELMI, SALEH M. SALEH, AHMED EL-SHAARAWY, MAHMOUD LOTFY
Primary Institution: National Liver Institute, Minufiya University, Minufiya, Egypt
Hypothesis
Does interferon-a treatment for chronic hepatitis C lead to the development of islet cell autoantibodies in patients?
Conclusion
Interferon-a treatment for chronic hepatitis C may induce islet cell autoantibodies in one-third of Egyptian patients with HCV4, but these do not affect glucose metabolism.
Supporting Evidence
- 2 out of 40 patients had detectable serum islet cell autoantibodies before treatment.
- 12 out of 38 previously negative patients developed islet cell autoantibodies after treatment.
- None of the patients developed impaired glucose tolerance or diabetes during follow-up.
Takeaway
Some patients getting treated for hepatitis C might develop antibodies that attack their pancreas, but it doesn't seem to make them sick with diabetes.
Methodology
40 Egyptian patients with chronic HCV4 were treated with interferon-a and ribavirin, and their serum samples were tested for islet cell autoantibodies before and after treatment.
Potential Biases
Potential bias due to the study being conducted in a single center and the specific population of Egyptian patients.
Limitations
The study is limited to a small sample size and specific demographic, which may not be generalizable.
Participant Demographics
40 Egyptian patients (38 males, mean age 32 years) with chronic hepatitis C.
Statistical Information
P-Value
0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website